First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...
MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...
According to the record, the trial status is “completed,” which means follow-up and data collection are finished and analysis can move forward. The most recent update was filed on 2026-02-10, ...
LAHORE: The Punjab government has decided to introduce state-of-the-art intravascular surgery techniques for the treatment of heart diseases, aiming to modernise cardiac care across the province. The ...
TOKYO--(BUSINESS WIRE)--DIC Corporation (TOKYO:4631) announced today that it will participate in CES 2026, one of the world’s leading technology trade shows for the consumer electronics industry, ...
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
SAN FRANCISCO – OCTOBER 26, 2025 – Results from the first randomized controlled trial to directly compare the safety and efficacy of cutting balloon (CB) angioplasty to intravascular lithotripsy (IVL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results